Page 79 - 2021_12-Haematologica-web

RA/arsenic activate a PML/P53 axis in NPM-1c AML
Acad Sci U S A. 1997;94(8):3978-3983.
23. Lehmann-Che J, Bally C, de The H. therapy resistance in APL. N Engl J Med.
2014;371(12):1171-1172.
24. Lehmann-Che J, Bally C, Letouze E, et al.
Dual origin of relapses in retinoic-acid resist- ant acute promyelocytic leukemia. Nat Commun. 2018;9(1):2047.
25. Jeanne M, Lallemand-Breitenbach V, Ferhi O, et al. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell. 2010;18(1):88-98.
26. Koken MHM, Linares-Cruz G, Quignon F, et al. The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene. 1995;10(7):1315-1324.
27. Gurrieri C, Capodieci P, Bernardi R, et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst. 2004;96(4):269-279.
28. Scaglioni PP, Yung TM, Cai LF, et al. A CK2- dependent mechanism for degradation of the PML tumor suppressor. Cell. 2006;126 (2):269-283.
29. Wu HC, Lin YC, Liu CH, et al. USP11 regu- lates PML stability to control Notch-induced malignancy in brain tumours. Nat Commun. 2014;5:3214.
30. Yuan WC, Lee YR, Huang SF, et al. A Cullin3-KLHL20 ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. Cancer Cell. 2011;20(2):214-228.
31. Fischer M. Census and evaluation of P53 tar- get genes. Oncogene. 2017;36(28):3943- 3956.
32. Lallemand-Breitenbach V, Jeanne M, Benhenda S, et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol. 2008;10(5):547-555.
33. Nabbouh AI, Hleihel RS, Saliba JL, et al. Imidazoquinoxaline derivative EAPB0503: a promising drug targeting mutant nucle- ophosmin 1 in acute myeloid leukemia. Cancer. 2017;123(9):1662-1673.
34. Dassouki Z, Sahin U, El Hajj H, et al. ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation. Blood. 2015;125(3):474- 482.
35. Stadler M, Chelbi-Alix MK, Koken MHM, et al. Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS ele- ment. Oncogene. 1995;11(12):2565-2573.
36.Reineke EL, Lam M, Liu Q, et al. Degradation of the tumor suppressor PML by Pin1 contributes to the cancer phenotype of breast cancer MDA-MB-231 cells. Mol Cell Biol. 2008;28(3):997-1006.
37. Mantovani F, Zannini A, Rustighi A, Del Sal G. Interaction of P53 with prolyl isomerases: healthy and unhealthy relationships. Biochim Biophys Acta. 2015;1850(10):2048- 2060.
38. Pearson M, Carbone R, Sebastiani C, et al. PML regulates P53 acetylation and prema- ture senescence induced by oncogenic Ras. Nature. 2000;406(6792):207-210.
39. de Stanchina E, Querido E, Narita M, et al. PML is a direct P53 target that modulates P53 effector functions. Mol Cell. 2004;13(4): 523-535.
40. Lo-Coco F, Di Donato L: GIMEMA, Schlenk RF: German-Austrian Acute Myeloid Leukemia Study Group and Study Alliance Leukemia. Targeted therapy alone for acute promyelocytic leukemia. N Engl J Med. 2016;374(12):1197-1198.
41. Altucci L, Rossin A, Hirsch O, et al. Rexinoid-triggered differentiation and
tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. Cancer Res. 2005;65(19):8754-8765.
42. Gu X, Ebrahem Q, Mahfouz RZ, et al. Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest. 2018;128(10):4260-4279.
43. Haindl M, Harasim T, Eick D, Muller S. The nucleolar SUMO-specific protease SENP3 reverses SUMO modification of nucle- ophosmin and is required for rRNA process- ing. EMBO Rep. 2008;9(3):273-279.
44. Kuo ML, den Besten W, Thomas MC, Sherr CJ. Arf-induced turnover of the nucleolar nucleophosmin-associated SUMO-2/3 pro- tease Senp3. Cell Cycle. 2008;7(21):3378- 3387.
45. Yun C, Wang Y, Mukhopadhyay D, et al. Nucleolar protein B23/nucleophosmin regu- lates the vertebrate SUMO pathway through SENP3 and SENP5 proteases. J Cell Biol. 2008;183(4):589-595.
46. Lim JH, Liu Y, Reineke E, Kao HY. Mitogen- activated protein kinase extracellular signal- regulated kinase 2 phosphorylates and pro- motes Pin1 protein-dependent promyelocyt- ic leukemia protein turnover. J Biol Chem. 2011;286(52):44403-44411.
47. Jain P, Konoplev S, Benjamini O, Romagura J, Burger JA. Long-term control of refractory follicular lymphoma after treatment of sec- ondary acute promyelocytic leukemia with arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA). Blood Res. 2018;53(2):169-172.
48. Alsafadi S, Even C, Falet C, al. Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013;13(5):401-408.
haematologica | 2021; 106(12)
3099